Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 14, 2020
Daily News
September 14, 2020
- EFPIA Japan Issues Statement on Vaccination System under COVID-19 Crisis, Calls for Eliminating Obstacles for Vaccine Imports
September 14, 2020
- AstraZeneca, PMDA Discussing Restart of COVID-19 Vaccine Trial in Japan
September 14, 2020
- Prioritized Flu Vaccinations for Elderly from October 1, Others Asked to Wait until October 26
September 14, 2020
- Additional Dosage of Edoxaban Filed in Japan for Elderly with High Bleeding Risk
September 14, 2020
- Japan to Officially Sign Up for COVAX Pact; Govt to Hammer Out Payment on Sept. 15
September 14, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…